umr glp 1 coverage Who Gets the Shot? GLP-1 Access by State Global Health Brief: The rise

Tirzepatide often leads to greater weight loss but may be associated with more gastrointestinal side effects

HOMA-IR, homeostasis model assessment of insulin resistance

The 30-year-old Lansing, Mich

The Medicines and Healthcare products Regulatory Agency (MHRA) and the European Medicines Agency (EMA) have conducted thorough reviews of pancreatic safety data for GLP-1 receptor agonists

Why the JPML Created a Separate MDL for NAION Claims One of the most important aspects of this decision is what the JPML did not do: rather than folding NAION claims into an already-existing GLP-1 products liability MDL, the panel chose to establish an entirely separate MDL dedicated specifically to NAION claims